Fred D. Lublin, M.D.
Icahn School of Medicine at Mount Sinai
Dr. Lublin is a neuroimmunologist with a special interest in immune functions and abnormalities that affect the nervous system. He currently serves as the Saunders Family Professor of Neurology and the Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai in New York. As one of the world’s foremost experts on experimental therapies for multiple sclerosis (MS), Dr. Lublin transformed patient outcomes with pioneering studies of Interferon beta-1b before the drug received approval from the U.S. Food and Drug Administration (FDA) in 1993 to treat the relapsing-remitting form of the disease. Over the years, his work has received funding from the National Institutes of Health (NIH), National Multiple Sclerosis Society (NMSS) and the International Progressive MS Alliance, among other organizations.
Dr. Lublin has served on the Board of MS Hope for a Cure and the National Multiple Sclerosis Society. He also served as past Chairman of the National Multiple Sclerosis Society (USA) advisory committee on clinical trials of new MS drugs and Chairman and National Board Member of the Clinical Advisory Committee of the New York City Chapter of the National MS Society. He has published numerous scientific articles and has served as a consultant to the NIH, as well as to pharmaceutical and biotechnology companies in all phases of drug development, including in preparation for drug presentation to the FDA and its advisory panels.
Dr. Lublin earned his medical degree from Jefferson Medical College in Philadelphia, PA and completed an externship at the National Hospital for Nervous Diseases in Queen Square, London. He concluded his formal training in New York with an internal medicine internship at Bronx Municipal Hospital, Albert Einstein Medical Center, and a neurology residency at New York Hospital, Cornell Medical Center. In 2018, Dr. Lublin received the Clifford H. Goldsmith Award for Outstanding Service and the June Halper Lifetime Achievement Award from the Consortium of MS Centers in recognition of his long-standing history of innovative research and commitment to excellence in caring for patients with MS.
Bruce E. Sands, M.D., M.S.
Icahn School of Medicine at Mount Sinai
Dr. Sands is the Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai in New York. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn’s & Colitis Center at Massachusetts General Hospital in Boston, where he also served as the hospital’s Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School.
A longtime advocate for continued translational research in Crohn’s disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. He was among the first to report the efficacy of infliximab, a drug used to treat autoimmune diseases in ulcerative colitis, a result later confirmed in large, multi-center randomized controlled trials.
Dr. Sands has served as the Chair of the Clinical Research Alliance of the Crohn’s Foundation of America, Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA) and Chair of the International Organization for the Study of IBD. He is an AGA fellow (AGAF) and a fellow of the American College of Gastroenterology (FACG). His work has appeared in several leading peer-reviewed journals, including the New England Journal of Medicine, for which he is also a reviewer, Gastroenterology and Gut. He served as an Associate Editor for the leading journal, Gastroenterology, from 2011 to 2016.
Dr. Sands received his medical degree at Boston University School of Medicine, MA and completed a residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. He completed his clinical and research fellowships at the Massachusetts General Hospital. Dr. Sands also holds a Master of Science in epidemiology from Harvard School of Public Health.
Jerrold R. Turner, M.D., Ph.D.
Harvard Medical School / Brigham and Women’s Hospital
Dr. Turner is a Professor of Pathology and Medicine at Harvard Medical School. Dr. Turner also serves as a Senior Pathologist in the Department of Pathology at Brigham and Women’s Hospital and directs the Laboratory of Mucosal Barrier Pathobiology. Work in the laboratory focuses on tight junction biology and intestinal diseases. These studies have been continuously funded by the National Institutes of Health for over 25 years.
Dr. Turner previously served as the Sara and Harold Lincoln Thompson Professor at the University of Chicago, and as Associate Chair and the Associate Residency Director in the department of Pathology at the University of Chicago. Earlier in his career, he was Assistant/Associate Professor of Pathology at Wayne State University School of Medicine.
Dr. Turner has been published in numerous scientific journals throughout his career. He is the Founding Editor-In-Chief of Cellular and Molecular Gastroenterology and Hepatology, the basic and translational science journal of the American Gastroenterological Association, and has served as the Associate Editor of Gastroenterology, the American Journal of Pathology, and Laboratory Investigation.
Dr. Turner earned his medical degree and Ph.D. from Case Western Reserve University and completed his residency in anatomic pathology at Brigham and Women’s Hospital, where he also completed clinical and research fellowships in gastrointestinal and hepatobiliary pathology. He is board certified in anatomic pathology.
Paul J. Utz, M.D.
Stanford University School of Medicine
Dr. Utz is an expert in the study of human and murine autoantibodies and autoantigens, apoptosis signaling pathways, animal models of autoimmunity, proteomics and multiplexed assay development for biomarker discovery. He is currently Professor of Medicine – Immunology & Rheumatology at the Stanford University School of Medicine, where he directs a lab focused on the normal immune system and how it differs with the immune system of patients with immunodeficiency disorders, infections, and autoimmune diseases. Among the autoimmune diseases being studied are systemic lupus erythematosus, rheumatoid arthritis, MS and IBD. In addition to trying to better understand the pathogenic mechanisms involved in autoimmune and inflammatory diseases, the lab is interested in developing bench-to-bedside technologies, including diagnostics and therapeutics, for human immune diseases.
In addition to his research, Dr. Utz has been an innovator in medical student education. He is the Stanford Associate Dean for Medical Student Research, focused on promoting physician investigator development across the physician-scientist career continuum, and is founder of the Stanford Institutes of Medical Research (SIMR), one of the country’s largest and most respected immersive high school research programs. He also serves as the Emeritus Director of the Medical Scientist Training Program (MSTP) at Stanford.
Dr. Utz has won numerous faculty teaching awards for his work in the Department of Medicine and Immunology Interdepartmental Ph.D. Program at Stanford, and elsewhere. He is a member of the Scientific Advisory Boards of several biotechnology and pharmaceutical companies, and has co-founded three Bay Area companies.
Dr. Utz earned his medical degree from the Stanford University School of Medicine. He completed his internal medicine residency, rheumatology fellowship, and post-doctoral training at Brigham and Women’s Hospital in Boston prior to joining the Harvard Medical School Faculty.